Association between microRNA‑527 and glypican‑3 in hepatocellular carcinoma

1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and

Roberts LR: A global view of hepatocellular carcinoma: Trends,

risk, prevention and management. Nat Rev Gastroenterol

Hepatol 16: 589‑604, 2019.

2. Wang CH, Wey KC, Mo LR, Chang KK, Lin RC and Kuo JJ:

Current trends and recent advances in diagnosis, therapy, and

prevention of hepatocellular carcinoma. Asian Pac J Cancer

Prev 16: 3595‑3604, 2015.

3. Sherman M: Hepatocellular carcinoma: Epidemiology,

surveillance, and diagnosis. Semin Liver Dis 30: 3‑16, 2010.

4. Iwama H, Masaki T and Kuriyama S: Abundance of microRNA

target motifs in the 3'‑UTRs of 20527 human genes. FEBS

Lett 581: 1805‑1810, 2007.

5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and

function. Cell 116: 281‑297, 2004.

6. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ,

MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al:

Combinatorial microRNA target predictions. Nat Genet 37:

495‑500, 2005.

7. Bartel DP: Metazoan MicroRNAs. Cell 173: 20‑51, 2018.

8. Tomasello L, Cluts L and Croce CM: Experimental validation

of microRNA targets: Mutagenesis of binding regions. Methods

Mol Biol 1970: 331‑339, 2019.

9. Meng F, Henson R, Wehbe‑Janek H, Ghoshal K, Jacob ST

and Patel T: MicroRNA‑21 regulates expression of the PTEN

tumor suppressor gene in human hepatocellular cancer.

Gastroenterology 133: 647‑658, 2007.

10. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H,

Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al:

Reduced expression of the let‑7 microRNAs in human lung

cancers in association with shortened postoperative survival.

Cancer Res 64: 3753‑3756, 2004.

11. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P,

Dienes HP and Odenthal M: MicroRNA gene expression profile

of hepatitis C virus‑associated hepatocellular carcinoma.

Hepatology 47: 1223‑1232, 2008.

12. Visone R and Croce CM: miRNAs and cancer. Am J Pathol 174:

1131‑1138, 2009.

13. Morishita A and Masaki T: miRNA in hepatocellular carcinoma.

Hepatol Res 45: 128‑141, 2015.

14. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD,

Shimizu M, Cimmino A, Zupo S, Dono M, et al: MicroRNA

profiling reveals distinct signatures in B cell chronic lymphocytic

leukemias. Proc Natl Acad Sci USA 101: 11755‑11760, 2004.

15. Sevignani C, Calin GA, Siracusa LD and Croce CM: Mammalian

microRNAs: A small world for fine‑tuning gene expression.

Mamm Genome 17: 189‑202, 2006.

16. Metzler M, Wilda M, Busch K, Viehmann S and Borkhardt A:

High expression of precursor microRNA‑155/BIC RNA

in children with Burkitt lymphoma. Genes Chromosomes

Cancer 39: 167‑169, 2004.

17. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP

and James RJ: Reduced accumulation of specific microRNAs in

colorectal neoplasia. Mol Cancer Res 1: 882‑891, 2003.

18. Tokarz P and Blasiak J: The role of microRNA in metastatic

colorectal cancer and its significance in cancer prognosis and

treatment. Acta Biochim Pol 59: 467‑474, 2012.

19. Del Vescovo V and Denti MA: microRNA and lung cancer. Adv

Exp Med Biol 889: 153‑177, 2015.

20. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM,

Qiao P, Zheng Y, Sheng YY, et al: MicroRNA‑26a suppresses

tumor growth and metastasis of human hepatocellular carcinoma

by targeting interleukin‑6‑Stat3 pathway. Hepatology 58:

158‑170, 2013.

21. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C and

Zhuang SM: MicroRNA‑26a/b and their host genes cooperate to

inhibit the G1/S transition by activating the pRb protein. Nucleic

Acids Res 40: 4615‑4625, 2012.

22. Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, Chung AYF,

Jooi LLP and Lee CG: Lethal‑7 is down‑regulated by the

hepatitis B virus x protein and targets signal transducer and

activator of transcription 3. J Hepatol 53: 57‑66, 2010.

23. Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X, Xie D, Shen Z, Sze J,

Li K, et al: MYC protein inhibits transcription of the microRNA

cluster MC‑let‑7a‑1~let‑7d via noncanonical E‑box. J Biol

Chem 286: 39703‑39714, 2011.

24. Tsang WP and Kwok TT: Let‑7a microRNA suppresses

therapeutics‑induced cancer cell death by targeting caspase‑3.

Apoptosis 13: 1215‑1222, 2008.

25. Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A,

Merkel AL, Quint K and Ocker M: Downregulation of HMGA2

by the pan‑deacetylase inhibitor panobinostat is dependent on

hsa‑let‑7b expression in liver cancer cell lines. Exp Cell Res 318:

1832‑1843, 2012.

NOMURA et al: ASSOCIATION BETWEEN miR‑527 AND GLYPICAN‑3 IN HEPATOCELLULAR CARCINOMA

26. Zhu XM, Wu LJ, Xu J, Yang R and Wu FS: Let‑7c microRNA

expression and clinical significance in hepatocellular carcinoma.

J Int Med Res 39: 2323‑2329, 2011.

27. Lan FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, Xie D,

He ML, Lin MC and Kung HF: Hsa‑let‑7g inhibits proliferation

of hepatocellular carcinoma cells by downregulation of c‑Myc

and upregulation of p16(INK4A). Int J Cancer 128: 319‑331,

2011.

28. Traister A, Shi W and Filmus J: Mammalian Notum induces the

release of glypicans and other GPI‑anchored proteins from the

cell surface. Biochem J 410: 503‑511, 2008.

29. Li N, Gao W, Zhang YF and Ho M: Glypicans as Cancer

Therapeutic Targets. Trends Cancer 4: 741‑754, 2018.

30. Capurro MI, Xu P, Shi W, Li F, Jia A and Filmus J: Glypican‑3

inhibits Hedgehog signaling during development by competing

with patched for Hedgehog binding. Dev Cell 14: 700‑711,

2008.

31. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N,

Takahashi S, Nakagohri T, Konishi M, Kobayashi N,

Kinoshita T, et al: Glypican‑3 expression is correlated with poor

prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403‑1407,

2009.

32. Zhang J, Zhang M, Ma H, Song X, He L, Ye X and Li X:

Overexpression of glypican‑3 is a predictor of poor prognosis in

hepatocellular carcinoma: An updated meta‑analysis. Medicine

(Baltimore) 97: e11130, 2018.

33. Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T,

Nishiyama N, Miyoshi H, Kobayashi M, Kobara H, et al:

Antidiabetic drug metformin inhibits esophageal adenocar‑

cinoma cell proliferation in vitro and in vivo. Int J Oncol 46:

2172‑2180, 2015.

34. Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J,

Katsura A, Tatsuta M, Maeda E, Mimura S, et al: Galectin‑9

suppresses the growth of hepatocellular carcinoma via apoptosis

in vitro and in vivo. Int J Oncol 46: 2419‑2430, 2015.

35. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison

of normalization methods for high density oligonucleotide array

data based on variance and bias. Bioinformatics 19: 185‑193,

2003.

36. Laemmli UK: Cleavage of structural proteins during the

assembly of the head of bacteriophage T4. Nature 227: 680‑685,

1970.

37. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer

of proteins from polyacrylamide gels to nitrocellulose sheets:

Procedure and some applications. Proc Natl Acad Sci USA 76:

4350‑4354, 1979.

38. Benjamini Y and Hochberg Y: Controlling the false discovery

rate: A practical and powerful approach to multiple testing.

J R Stat Soc B 57: 289‑300, 1995.

39. Chen Y‑H, Song Y, Yu YL, Cheng W and Tong X: miRNA‑10a

promotes cancer cell proliferation in oral squamous cell

carcinoma by upregulating GLUT1 and promoting glucose

metabolism. Oncol Lett 17: 5441‑5446, 2019.

40. Pal R and Greene S: microRNA‑10b is overexpressed and critical

for cell survival and proliferation in medulloblastoma. PLoS

One 10: e0137845, 2015.

41. Werk AN, Bruckmueller H, Haenisch S and Cascorbi I: Genetic

variants may play an important role in mRNA‑miRNA inter‑

action: Evidence for haplotype‑dependent downregulation of

ABCC2 (MRP2) by miRNA‑379. Pharmacogenet Genomics 24:

283‑291, 2014.

42. Nishida T and Kataoka H: Glypican 3‑targeted therapy in hepa‑

tocellular carcinoma. Cancers (Basel) 11: E1339, 2019.

43. Vongchan P and Linhardt RJ: Characterization of a new mono‑

clonal anti‑glypican‑3 antibody specific to the hepatocellular

carcinoma cell line, HepG2. World J Hepatol 9: 368‑384, 2017.

44. Singh AK, Kumar R and Pandey AK: Hepatocellular Carcinoma:

Causes, Mechanism of Progression and Biomarkers. Curr Chem

Genomics Transl Med 12: 9‑26, 2018.

45. Zhou F, Shang W, Yu X and Tian J: Glypican‑3: A promising

biomarker for hepatocellular carcinoma diagnosis and treatment.

Med Res Rev 38: 741‑767, 2018.

46. Wang L, Yao M, Pan LH, Qian Q and Yao DF: Glypican‑3 is a

biomarker and a therapeutic target of hepatocellular carcinoma.

Hepatobiliary Pancreat Dis Int 14: 361‑366, 2015.

47. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK,

Guerrero RB, Aderca I, Isomoto H, Garrity‑Park MM, et al:

Sulfatase 2 up‑regulates glypican 3, promotes fibroblast growth

factor signaling, and decreases survival in hepatocellular

carcinoma. Hepatology 47: 1211‑1222, 2008.

48. Huo W, Zhu XM, Pan XY, Du M, Sun Z and Li ZM: MicroRNA‑527

inhibits TGF‑β/SMAD induced epithelial‑mesenchymal tran‑

sition via downregulating SULF2 expression in non‑small‑cell

lung cancer. Math Biosci Eng 16: 4607‑4621, 2019.

This work is licensed under a Creative Commons

Attribution-NonCommercial-NoDerivatives 4.0

International (CC BY-NC-ND 4.0) License.

...